Search

Theme

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1.

Tuning of cytokine signaling through imbalanced abundances of receptors and kinases

Team: Innate lymphoid cells

Publication: IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies